Voyager Therapeutics Enters into a Collaboration and License Agreement with Novartis to Advance Novel Gene Therapies for Huntington’s Disease (HD) and Spinal Muscular Atrophy (SMA)
Shots:
- The agreement was signed to advance potential gene therapies for HD & SMA as Voyager agrees to grant Novartis access to TRACER capsid and other IPs
- As per the agreement, Voyager will receive $100M as up front payment incl. $20M purchase of newly issued equity & is eligible to receive up to $1.2B in preclinical, development, regulatory & sales milestones plus tiered royalties
- Novartis will obtain target-exclusive access to Voyager’s TRACER capsids related to SMA & will be responsible for all development & commercialization activities. Novartis will also receive the worldwide rights to Voyager’s AVV gene therapy for HD & will oversee clinical development & commercialization of the HD program (preclinical advancement by Voyager)
Ref: Voyager Therapeutics | Image: Voyager Therapeutics
Related News:- Neurocrine and Voyager Collaborated to Develop Multiple Gene Therapies for the Treatment of Neurological Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
